Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users

BACKGROUND: Lemborexant (LEM) is a dual orexin receptor antagonist approved for the treatment of insomnia in adults in multiple countries including the the United States, Japan, Canada, Australia and several Asian countries. PROCEDURES: This was a randomized, single-dose, single-center, double-blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Landry, Ishani, Hall, Nancy, Aluri, Jagadeesh, Filippov, Gleb, Reyderman, Larisa, Setnik, Beatrice, Henningfield, Jack, Moline, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257054/
https://www.ncbi.nlm.nih.gov/pubmed/35749758
http://dx.doi.org/10.1097/JCP.0000000000001561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257054/
https://www.ncbi.nlm.nih.gov/pubmed/35749758
http://dx.doi.org/10.1097/JCP.0000000000001561

Ejemplares similares